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Background: Elevation of cardiac troponin confers worse prognosis in patients with acute coronary syndromes (ACS). However the prognostic value 
of troponin elevation in patients with chronic renal insufficiency(CRI) is less certain.
Methods and Results: In ACUITY, among a total of 13,819 patients, 2179 (15.7%) patients had CRI (CrCl <60mL/min). The primary end point 
was net clinical outcome including MACE (death, myocardial infarction and unplanned revascularization) and major bleeding at 30 days. Outcomes 
were stratified as a function of troponin status. As shown in the table, patients with positive troponin had significantly higher rates of death and MI 
resulting in higher rates of MACE at 30 days and 1 year. By multivariable analysis, troponin elevation was an independent predictor of mortality at 30 
days (odds ratio [95% confidence interval] = 4.75 [2.34, 9.65], P<0.0001) and 1 year (odds ratio [95% confidence interval] = 1.58 [1.12, 2.23], 
P=0.009). One-year MI was also predicted by elevated troponin (odds ratio [95% confidence interval] = 1.54 [1.05, 2.25], P=0.023)
Conclusions: In patients with ACS and CRI, troponin elevation is associated with remarkably worse short- and long-term clinical ischemic 
outcomes including significantly elevated rates of mortality and MI. 
Endpoints, %
Patients with chronic renal insufficiency N=2179
P-valueTroponin (+)
N=1291
Troponin (-)
N=888
At 30 days
Death 60 (4.7%) 9 (1.0%) <0.0001
Myocardial infarction 106 (8.3%) 44 (5.0%) 0.003
Q-wave 22 (1.7%) 8 (0.9%) 0.10
Non Q-wave 84 (6.6%) 38 (4.3%) 0.02
Unplanned revasc 45 (3.6%) 25 (2.8%) 0.33
Major bleeding 132 (10.3%) 76 (8.6%) 0.16
Composite ischemia 175 (13.6%) 70 (7.9%) <0.0001
At 1 year
Death 127 (10.7%) 51 (6.8%) 0.0005
Myocardial infarction 165 (13.3%) 63 (7.3%) <0.0001
Q-wave 29 (2.3%) 10 (1.1%) 0.046
Non Q-wave 136 (11.0%) 56 (6.5%) 0.0004
Unplanned revasc 117 (10.0%) 89 (11.2%) 0.65
Composite ischemia 310 (25.2%) 166 (20.6%) 0.002
